Tempest Therapeutics Inc (NASDAQ:TPST) released new results from an ongoing Phase 1b/2 study of TPST-1120 in the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC). The study shows TPST-1120's clinical superiority in multiple endpoints when combined with atezolizumab and bevacizumab. The confirmed objective response rate was 30% for the TPST-1120 arm versus 13.3% for the control arm. The progression-free survival was a median of 7 months for the TPST-1120 arm versus 4.27 months for the control arm. TPST shares are up 800.40% at $2.16 during the premarket session on the last check Wednesday.